Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azelastine/mometasone intranasal - Sandoz

Next Previous
Drug Profile

Azelastine/mometasone intranasal - Sandoz

Alternative Names: Mometasone/azelastine - Sandoz

Latest Information Update: 28 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sandoz
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Azepines; Chlorinated hydrocarbons; Furans; Glucocorticoids; Ketones; Phenanthrenes; Phthalazines; Pregnadienediols; Skin disorder therapies; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 28 Jul 2026 No recent reports of development identified for phase-I development in Seasonal-allergic-rhinitis in Canada (Intranasal, Spray)
  • 08 Sep 2023 Sandoz terminates a phase I trial in Seasonal allergic rhinitis (In adolescents, In adults) in Canada (Intranasal) as per the business decision (NCT05887843) (EudraCT2023-000362-34)
  • 13 Jun 2023 Preclinical trials in Seasonal allergic rhinitis in Germany (Intranasal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top